Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases

CONCLUSIONS: The observed response rate and safety of SG are consistent with the results of the ASCENT trial, with efficacy observed in patients with brain metastases, but observed PFS and OS are numerically shorter.PMID:38600429 | DOI:10.1007/s12282-024-01565-7

Source: Breast Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Alexandre De Moura Delphine Loirat Sarah Vaillant Sinen Korbi Nicolas Kiavue Diana Bello Roufai Laurence Escalup Romain Desmaris Pauline Vaflard Paul Cottu Jean-Yves Pierga Fran çois-Clément Bidard Luc Cabel Alexandre Acramel Source Type: research